Related Experiment Video
Updated: Jul 7, 2025
Retroductal Submandibular Gland Instillation and Localized Fractionated Irradiation in a Rat Model of Salivary Hypofunction
Published on: April 24, 2016
Systemic therapies for salivary gland carcinomas: an overview of published clinical trials
L-C Silva1, M-E Pérez-de-Oliveira, C-M Pedroso
1Department of Oral Diagnosis Piracicaba Dental School, University of Campinas Av Limeira, 901, Postal code:13414-016, Piracicaba, São Paulo, Brasil pavargas@unicamp.br.
Background:
There is no consensus about effective systemic therapy for salivary gland carcinomas (sgcs). Our aim was summarized the clinical trials assessing the systemic therapies (ST) on sgcs.
Material And Methods:
Electronic searches were carried out through MEDLINE/pubmed, EMBASE, Scopus, Web of Science, and the Cochrane Library databases, and gray literature.
Results:
Seventeen different drugs were evaluated, and the most frequent histological subtype was adenoid cystic carcinoma (n=195, 45.5%). Stable disease, observed in 11 ST, achieved the highest rate in adenoid cystic carcinoma treated with sunitinib. The highest complete (11.1%) and partial response (30.5%) rates were seen in androgen receptor-positive tumors treated with leuprorelin acetate.
Conclusions:
Despite all the advances in this field, there is yet no effective evidence-based regimen of ST, with all the clinical trials identified showing low rates of complete and partial responses. Further, translational studies are urgently required to characterize molecular targets and effective ST.
Insights
Systemic therapies (ST) for salivary gland carcinomas (sgcs) lack consensus. Clinical trials show low response rates, highlighting the need for molecular target identification and effective ST development.
Area of Science:
- Oncology
- Medical Research
- Clinical Trials
Background:
- Salivary gland carcinomas (sgcs) lack a consensus for effective systemic therapy (ST).
- Current treatment strategies for sgcs require further investigation and validation.
- Understanding the efficacy of different systemic therapies is crucial for improving patient outcomes.
Purpose of the Study:
- To summarize clinical trials assessing systemic therapies (ST) for salivary gland carcinomas (sgcs).
- To evaluate the effectiveness of various drugs in treating different histological subtypes of sgcs.
- To identify potential therapeutic targets and effective ST regimens for sgcs.
Main Methods:
- Comprehensive electronic searches were conducted across major databases including MEDLINE/PubMed, EMBASE, Scopus, Web of Science, and the Cochrane Library.
- Gray literature was also included to ensure a thorough review of available clinical trials.
- Seventeen different drugs were evaluated across the identified studies.
Main Results:
- Adenoid cystic carcinoma was the most frequent histological subtype (45.5%).
- Sunitinib showed the highest rate of stable disease in adenoid cystic carcinoma.
- Leuprorelin acetate demonstrated the highest complete (11.1%) and partial (30.5%) response rates in androgen receptor-positive tumors.
Conclusions:
- Despite advances, no evidence-based ST regimen is established for sgcs.
- All identified clinical trials reported low rates of complete and partial responses.
- Further translational studies are essential to identify molecular targets and develop effective ST for sgcs.
More Related Videos
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy